HKSE:2617

TransThera Sciences (Nanjing). Inc. · HKSE · Healthcare · HKD · FY for 2025

Figures on this page computed 2026-11-08 13:44 UTC

Last close

n/aHKD

Market data

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aNet margin
We do not hold this figure for this company, so there is nothing to place.
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed

Price is the furthest below its sector's middle: 0.15 against 0.45 on the market's range.

Margins: n/aWe do not hold this figure for this company, so there is nothing to place.
What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Then and now

lens 3 of 9

Five filed facts, 2020 against 2025.
Fact	2020	2025	Change
Sales	61,763,514	n/a	n/a
Profit	-80,716,325	-295,964,000	-267%
Free cash flow	-76,611,112	-253,675,000	-231%
Debt	490,744,281	1,646,000	-99.7%
Shares in issue	396,897,633	389,654,858	-1.8%

The same five facts for 2020 and 2025, each read from the year's own filing.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2020

Sales, 202061,763,514
Source
computed
Statement
income
Fiscal year
2020
Reported in
CNY
Sales, 2025n/aComputed from the filing for 2025
Not held.
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Profit, 2020-80,716,325
Source
computed
Statement
income
Fiscal year
2020
Reported in
CNY
Profit, 2025-295,964,000Computed from the filing for 2025
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Free cash flow, 2020-76,611,112
Source
computed
Statement
income
Fiscal year
2020
Reported in
CNY
Free cash flow, 2025-253,675,000Computed from the filing for 2025
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Debt, 2020490,744,281
Source
computed
Statement
income
Fiscal year
2020
Reported in
CNY
Debt, 20251,646,000Computed from the filing for 2025
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Shares in issue, 2020396,897,633
Source
computed
Statement
income
Fiscal year
2020
Reported in
CNY
Shares in issue, 2025389,654,858Computed from the filing for 2025
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY